Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 164

1.

Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.

van der Flier FE, Kwee CMB, Cath DC, Batelaan NM, Groenink L, Duits P, van der Veen DC, van Balkom AJLM, Baas JMP.

BMC Psychiatry. 2019 Feb 13;19(1):69. doi: 10.1186/s12888-019-2022-x.

PMID:
30760241
2.

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

White CM.

J Clin Pharmacol. 2019 Feb 7. doi: 10.1002/jcph.1387. [Epub ahead of print] Review.

PMID:
30730563
3.

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG.

Eur Arch Psychiatry Clin Neurosci. 2019 Jan 31. doi: 10.1007/s00406-019-00982-6. [Epub ahead of print] Review.

PMID:
30706171
4.

US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions.

Kogan L, Schoenfeld-Tacher R, Hellyer P, Rishniw M.

Front Vet Sci. 2019 Jan 10;5:338. doi: 10.3389/fvets.2018.00338. eCollection 2018.

5.

Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.

Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, Koren G, Berkovitch M.

Front Pharmacol. 2019 Jan 9;9:1521. doi: 10.3389/fphar.2018.01521. eCollection 2018.

6.

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L.

Biomed Res Int. 2018 Dec 4;2018:1691428. doi: 10.1155/2018/1691428. eCollection 2018. Review.

7.

Cannabidiol in Anxiety and Sleep: A Large Case Series.

Shannon S, Lewis N, Lee H, Hughes S.

Perm J. 2019;23. pii: 18-041. doi: 10.7812/TPP/18-041.

8.

Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus: Cannabidiol Blunts Δ9-Tetrahydrocannabinol-Induced Cognitive Impairment.

Aso E, Fernández-Dueñas V, López-Cano M, Taura J, Watanabe M, Ferrer I, Luján R, Ciruela F.

Mol Neurobiol. 2019 Jan 4. doi: 10.1007/s12035-018-1456-3. [Epub ahead of print]

PMID:
30610611
9.

Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies.

Lisboa SF, Vila-Verde C, Rosa J, Uliana DL, Stern CAJ, Bertoglio LJ, Resstel LB, Guimaraes FS.

Psychopharmacology (Berl). 2019 Jan;236(1):201-226. doi: 10.1007/s00213-018-5127-x. Epub 2019 Jan 2. Review.

PMID:
30604182
10.

Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.

Elms L, Shannon S, Hughes S, Lewis N.

J Altern Complement Med. 2018 Dec 13. doi: 10.1089/acm.2018.0437. [Epub ahead of print]

PMID:
30543451
11.

Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors.

Szkudlarek HJ, Desai SJ, Renard J, Pereira B, Norris C, Jobson CEL, Rajakumar N, Allman BL, Laviolette SR.

Neuropsychopharmacology. 2019 Mar;44(4):817-825. doi: 10.1038/s41386-018-0282-7. Epub 2018 Nov 27.

PMID:
30538288
12.

Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.

Scheidweiler KB, Barnes AJ.

Methods Mol Biol. 2019;1872:11-22. doi: 10.1007/978-1-4939-8823-5_2.

PMID:
30350275
13.

Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells.

Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, Holzmann K, Lavorgna M, Isidori M, Knasmüller S.

Arch Toxicol. 2019 Jan;93(1):179-188. doi: 10.1007/s00204-018-2322-9. Epub 2018 Oct 19.

14.

Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.

Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, Crippa JA.

Braz J Psychiatry. 2019 Jan-Mar;41(1):9-14. doi: 10.1590/1516-4446-2017-0015. Epub 2018 Oct 11.

15.

New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders.

Scherma M, Masia P, Deidda M, Fratta W, Tanda G, Fadda P.

Medicines (Basel). 2018 Oct 2;5(4). pii: E107. doi: 10.3390/medicines5040107. Review.

16.

Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.

De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, Aboud M, Maione S, Comai S, Gobbi G.

Pain. 2019 Jan;160(1):136-150. doi: 10.1097/j.pain.0000000000001386.

17.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2018 Aug 23. doi: 10.5740/jaoacint.18-0208. [Epub ahead of print]

PMID:
30139415
18.

A Cross-Sectional Study of Cannabidiol Users.

Corroon J, Phillips JA.

Cannabis Cannabinoid Res. 2018 Jul 1;3(1):152-161. doi: 10.1089/can.2018.0006. eCollection 2018.

19.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

20.

Supplemental Content

Loading ...
Support Center